Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.39 |
| ▸ | F2R | P25116 | 9/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20928257 | 0.81 | CHRNB2 (0.47) | HTR1ADRD2DRD4GLSKDM4E | |
| SCHEMBL3663509 | 0.78 | GLS (0.41) | HTR1ADRD2DRD4GLS | |
| SCHEMBL29306574 | 0.78 | NAAA (0.53) | HTR1ADRD2DRD4KDM4EHTT | |
| SCHEMBL13702331 | 0.77 | HTR1A (0.41) | HTR1ADRD2DRD4GLSKDM4E | |
| SCHEMBL47362 | 0.77 | GLS (0.40) | HTR1ADRD2DRD4GLS | |
| SCHEMBL16768104 | 0.76 | HTR1A (0.45) | HTR1ADRD2DRD4 | |
| SCHEMBL3199095 | 0.76 | NAAA (0.53) | ITGB3ITGA2BF2R | |
| SCHEMBL10499072 | 0.75 | HTR1A (0.44) | HTR1ADRD2DRD4ITGB3ITGA2B | |
| SCHEMBL24654177 | 0.74 | HSD17B10 (0.43) | HTR1ADRD2DRD4HTT | |
| SCHEMBL12999518 | 0.74 | ITGB3 (0.43) | ITGB3ITGA2BF2RKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | HTR1A 270/4885DRD2 1175/4885DRD4 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.